VYGR - Voyager Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Voyager Therapeutics, Inc.

75 Sidney Street
Cambridge, MA 02139
United States
857-259-5340
http://www.voyagertherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees123

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew P. OttmerChief Operating Officer545.67kN/A1971
Dr. Steven M. PaulExec. Science Advisor & DirectorN/AN/A1951
Mr. G. Andre TurenneCEO, Pres & DirectorN/AN/A1974
Dr. Krystof Bankiewicz M.D., Ph.D.FounderN/AN/AN/A
Dr. Guangping Gao Ph.D.FounderN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Voyager Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.